Novocure (NVCR) announced that Spain’s Ministry of Health has made Tumor Treating Fields therapy available through the Spanish National Health System for the treatment of adult patients with newly diagnosed glioblastoma. Patients with newly diagnosed glioblastoma who meet eligibility requirements defined by Spain’s Ministry of Health will be able to access TTFields therapy through hospitals and health centers qualified to offer the treatment.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure submits Tumor Treating Fields therapy premarket approval application
- NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer?
- Novocure’s Earnings Call: Clinical Successes & Cautious Optimism
- Positive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments
- Novocure Ltd. Reports Q2 2025 Financial Results